We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
251
Omeros
OMER
$836M
$369K 0.02%
23,450
-18,927
-45% -$261K
MCRB icon
252
Seres Therapeutics
MCRB
$45.8M
$368K 0.02%
525
-2,714
-84% -$1.78M
RPTP
253
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$368K 0.02%
707
-6,582
-90% -$38.2K
MGNX icon
254
CALL
MacroGenics
MGNX
$236M
$353K 0.02%
114
– –
FOCL
255
PUT
EDAP TMS S.A.
FOCL
$229M
$349K 0.02%
846
-620
-42% -$2.94K
PRQR icon
256
ProQR Therapeutics
PRQR
$247M
$346K 0.02%
39,871
+17,921
+82% +$206K
QURE icon
257
PUT
uniQure
QURE
$2.78B
$344K 0.02%
208
– –
ENDP
258
PUT
DELISTED
Endo International plc
ENDP
$337K 0.02%
55
-169
-75% -$10.3K
PGEN icon
259
Precigen
PGEN
$1.96B
$331K 0.02%
+11,094
New +$374K
LITS
260
Lite Strategy Inc
LITS
$32.4M
$320K 0.02%
10,000
-4,775
-32% -$164K
SPNC
261
CALL
DELISTED
Spectranetics Corp
SPNC
$316K 0.02%
+210
New +$2.77K
ARCT icon
262
CALL
Arcturus Therapeutics
ARCT
$161M
$314K 0.02%
+71
New +$3.2K
ZSAN
263
DELISTED
Zosano Pharma Corporation
ZSAN
$287K 0.02%
184
-49
-21% -$95.5K
DERM
264
PUT
DELISTED
Dermira, Inc.
DERM
$280K 0.02%
+100
New +$2.87K
HRTX icon
265
CALL
Heron Therapeutics
HRTX
$92.2M
$278K 0.02%
104
-4,119
-98% -$110K
RPRX
266
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$276K 0.02%
2,277
-500
-18% -$1.6K
HSTO
267
DELISTED
Histogen Inc. Common Stock
HSTO
$254K 0.01%
441
+128
+41% +$89.7K
FOLD
268
DELISTED
Amicus Therapeutics
FOLD
$249K 0.01%
+25,661
New +$231K
APEN
269
DELISTED
Apollo Endosurgery, Inc.
APEN
$249K 0.01%
14,375
+269
+2% +$4.53K
MGNX icon
270
PUT
MacroGenics
MGNX
$236M
$248K 0.01%
+80
New +$2.43K
MCRB icon
271
CALL
Seres Therapeutics
MCRB
$45.8M
$235K 0.01%
+3
New +$1.97K
AVDL
272
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
$232K 0.01%
+190
New +$2.96K
QURE icon
273
uniQure
QURE
$2.78B
$217K 0.01%
+13,131
New +$243K
AMRN
274
PUT
Amarin Corp
AMRN
$301M
$211K 0.01%
56
– –
VYNT
275
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$209K 0.01%
+422
New +$305K
9 10
11
12 13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.